Skip to main content

Connect Biopharma Holdings Ltd

corporate_fare Company Profile

Connect Biopharma Holdings Ltd

CNTB·NASDAQ·Life Sciences·CIK 0001835268

Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on improving care for asthma and chronic obstructive pulmonary disease (COPD). The company is developing rademikibart, an antibody designed to target interleukin-4-receptor alpha (IL-4Rα). Asthma is a chronic inflammatory lung disease affecting an estimated 23 million adults and 5 million children in the U.S. Globally, asthma affected an estimated 262 million people in 2019 and caused 455,000 deaths. The disease is associated with severe flare-ups that are challenging to treat and often lead to hospitalization. Approximately one million asthma patients visit emergency departments annually, with about 11% of these requiring hospitalization for an average of two to three days. Approximately 50% of asthma patients who visit emergency departments experience treatment failure within four weeks of a flare-up. About 20% of these patients need to revisit the emergency department, and an additional 30% seek medical care from other sources like urgent care or clinics. Current standard treatments include fast-acting inhaled bronchodilators and oral or intravenous (IV) corticosteroids. Severe cases may require IV magnesium sulfate, heliox therapy, and noninvasive ventilation, with intubation considered if initial therapies are ineffective. Approximately 50% of patients do not improve with first-line treatments.

Connect Biopharma Holdings Ltd (NASDAQ:CNTB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CNTB at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Connect Biopharma Secures $20.2M Private Placement

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$64K
Net Income
-$55.48M
Diluted EPS
-$1.00
Op. Cash Flow
-$51.21M
Free Cash Flow
-$51.64M
Operating Income
-$58.07M
Cash & Equivalents
$38.34M
Debt / Equity
0.00×
Net Margin
-866.88×
Shares Outstanding
56.44M sh
Source: 10-K · filed 2026-03-31 · accession 0001835268-26-000013
$0.58 -1.69% today
52-week range · as of 2026-11-16 $0.58 – $3.82
Market cap
$38.05M
Volume
366K (0.5× avg)
3-mo avg 752.4K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CNTB - Filings & News (Page 2)

CNTB
Mar 30, 2026, 7:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.48
Real-time Price: $0.580 info
Change: -$2.90 (-83%) info
Market Cap: $38.048M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets